Pet Cancer Therapeutics Market By Size, Share, Trends, Growth, Forecast 2027

Summary

Report Description

The global pet cancer therapeutics market is anticipated to observe an impressive growth during the forecast period, 2023-2027. The major factors include growing consciousness of pet’s health and increasing incidences of cancer among animals. Cancer in pets is one of the primary reasons for death, globally. Nowadays, pets have better chances to get diagnosed with cancer due which early adoption of treatment plans are required, which bolster the growth of the market. The other factors supporting the market's growth are rise in pet ownership or animal adoption, advancement in diagnostic techniques and rise in R&D initiatives. Additionally, heavy investments in research and development activities coupled with oncology treatment and management in pets offers lucrative opportunities to the market players in upcoming years.

Increasing Awareness regarding Pet Healthcare and Treatments

The increasing domestication of animals and growing concerns regarding pet health among the people are supporting the market growth. In 2021, number of pet dogs owned worldwide was 471 million. People are becoming more thoughtful about their pet’s health and are expending generously on the best available animal therapeutics. Average American yearly spending on pet dogs is estimated to be USD 1201. In addition, growing pet’s health awareness programs is augmenting the growth of the market. For instance, the Blue Buffalo Foundation and the Pet Cancer Awareness Program (PCA) are some initiatives which raise awareness and provide information to the pet parents.

Increasing Prevalence of Cancer

The growing prevalence of cancer among pet animals, is a contributing factor for the growth of the market. Cancer is one of the key causes of death in pets, mostly in dogs that are older than 10 years. According to the Veterinary Cancer Society, in 2017, cancer was the foremost cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats. Leukemia and lymphoma are very common cancer in cats and certain breeds of elderly dogs. In 2017, Animal Cancer Foundation published a study, which revealed approximately around 25% of all dogs will develop a tumor at some point in their life.

Technological Advancements

Various technological advancements, such as the development of highly targeted and specific cures for animal cancer treatment with minimal side effects, are also supporting the market growth. Increasing R&D initiatives for cancer management is propelling the market growth, as various anti-cancer therapies are launching for veterinary cancer treatment. For instance, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to generate a biobank of dog tumors for giving insights on cancer cure through research. Also, organizations such as Animal Cancer Foundation, Veterinary Cancer Society, Petco Foundation and PetCure Oncology are doing oncology research such as canine cancer genome project to gain the knowledge related to the genetic makeup of cancer tumors in animals. The foremost focus is on the development of anticancer drugs and improvising their effectiveness and reducing their toxic effects on the pet’s body.

Download Free Sample Report

Market Segmentation

The global pet cancer therapeutics market is segmented into therapy, animal type, cancer type, and company. Based on therapy, the market is divided into surgery, radiotherapy, chemotherapy, immunotherapy, and others. Based on animal type, the market is divided into canine, feline, and others. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising domestication and rise in the occurrence of pet cancers in the country.

Market Players

C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are some of the leading companies operating in the market.

Attribute	Details
Base Year	2021
Historic Data	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027
Report coverage	Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends
Segments covered	· Therapy · Animal Type · Cancer Type · Region
Regional scope	North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa
Key companies profiled	C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global pet cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

· Pet Cancer Therapeutics Market, By Therapy:

Surgery
Radiotherapy
Chemotherapy
Immunotherapy
Others

· Pet Cancer Therapeutics Market, By Animal Type:

Canine
Feline
Others

· Pet Cancer Therapeutics Market, By Cancer Type:

Lymphoma
Mast Cell Cancer
Mammary & Squamous Cell Cancer
Others

· Pet Cancer Therapeutics Market, By Region:

North America

United States
Canada
Mexico

Asia-Pacific

China
India
Japan
Australia
South Korea

Europe & CIS

Germany
France
United Kingdom
Spain
Italy

South America

Brazil
Argentina
Colombia

Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Pet Cancer Therapeutics Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Pet Cancer Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Pet Cancer Therapeutics Market

5. Voice of Customer

6. Global Pet Cancer Therapeutics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)

6.2.2. By Animal Type (Canine, Feline, Others)

6.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)

6.2.4. By Company (2021)

6.2.5. By Region

6.3. Market Map

7. North America Pet Cancer Therapeutics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Therapy

7.2.2. By Animal Type

7.2.3. By Cancer Type

7.2.4. By Country

7.3. North America: Country Analysis

7.3.1. United States Pet Cancer Therapeutics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Therapy

7.3.1.2.2. By Animal Type

7.3.1.2.3. By Cancer Type

7.3.2. Mexico Pet Cancer Therapeutics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Therapy

7.3.2.2.2. By Animal Type

7.3.2.2.3. By Cancer Type

7.3.3. Canada Pet Cancer Therapeutics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Therapy

7.3.3.2.2. By Animal Type

7.3.3.2.3. By Cancer Type

8. Europe Pet Cancer Therapeutics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Therapy

8.2.2. By Animal Type

8.2.3. By Cancer Type

8.2.4. By Country

8.3. Europe: Country Analysis

8.3.1. France Pet Cancer Therapeutics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Therapy

8.3.1.2.2. By Animal Type

8.3.1.2.3. By Cancer Type

8.3.2. Germany Pet Cancer Therapeutics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Therapy

8.3.2.2.2. By Animal Type

8.3.2.2.3. By Cancer Type

8.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Therapy

8.3.3.2.2. By Animal Type

8.3.3.2.3. By Cancer Type

8.3.4. Italy Pet Cancer Therapeutics Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Therapy

8.3.4.2.2. By Animal Type

8.3.4.2.3. By Cancer Type

8.3.5. Spain Pet Cancer Therapeutics Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Therapy

8.3.5.2.2. By Animal Type

8.3.5.2.3. By Cancer Type

9. Asia-Pacific Pet Cancer Therapeutics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Therapy

9.2.2. By Animal Type

9.2.3. By Cancer Type

9.2.4. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China Pet Cancer Therapeutics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Therapy

9.3.1.2.2. By Animal Type

9.3.1.2.3. By Cancer Type

9.3.2. India Pet Cancer Therapeutics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Therapy

9.3.2.2.2. By Animal Type

9.3.2.2.3. By Cancer Type

9.3.3. Japan Pet Cancer Therapeutics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Therapy

9.3.3.2.2. By Animal Type

9.3.3.2.3. By Cancer Type

9.3.4. South Korea Pet Cancer Therapeutics Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Therapy

9.3.4.2.2. By Animal Type

9.3.4.2.3. By Cancer Type

9.3.5. Australia Pet Cancer Therapeutics Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Therapy

9.3.5.2.2. By Animal Type

9.3.5.2.3. By Cancer Type

10. South America Pet Cancer Therapeutics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Therapy

10.2.2. By Animal Type

10.2.3. By Cancer Type

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Pet Cancer Therapeutics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Therapy

10.3.1.2.2. By Animal Type

10.3.1.2.3. By Cancer Type

10.3.2. Argentina Pet Cancer Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Therapy

10.3.2.2.2. By Animal Type

10.3.2.2.3. By Cancer Type

10.3.3. Colombia Pet Cancer Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Therapy

10.3.3.2.2. By Animal Type

10.3.3.2.3. By Cancer Type

11. Middle East and Africa Pet Cancer Therapeutics Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Therapy

11.2.2. By Animal Type

11.2.3. By Cancer Type

11.2.4. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa Pet Cancer Therapeutics Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Therapy

11.3.1.2.2. By Animal Type

11.3.1.2.3. By Cancer Type

11.3.2. Saudi Arabia Pet Cancer Therapeutics Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Therapy

11.3.2.2.2. By Animal Type

11.3.2.2.3. By Cancer Type

11.3.3. UAE Pet Cancer Therapeutics Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Therapy

11.3.3.2.2. By Animal Type

11.3.3.2.3. By Cancer Type

11.3.4. Egypt Pet Cancer Therapeutics Market Outlook

11.3.4.1. Market Size & Forecast

11.3.4.1.1. By Value

11.3.4.2. Market Share & Forecast

11.3.4.2.1. By Therapy

11.3.4.2.2. By Animal Type

11.3.4.2.3. By Cancer Type

11.3.5. Turkey Pet Cancer Therapeutics Market Outlook

11.3.5.1. Market Size & Forecast

11.3.5.1.1. By Value

11.3.5.2. Market Share & Forecast

11.3.5.2.1. By Therapy

11.3.5.2.2. By Animal Type

11.3.5.2.3. By Cancer Type

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

14.1. C.H. Boehringer Sohn Ko. KG

14.2. ELIAS Animal Health, LLC

14.3. Zoetis Inc.

14.4. AB Science S.A.

14.5. Karyopharm Therapeutics, Inc.

14.6. Vivesto AB

14.7. Merial Inc.

14.8. Elanco Animal Health, Inc.

14.9. Dechra Pharmaceuticals PLC (Anivive Lifesciences)

14.10. Torigen Pharmaceuticals Inc.

15. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Pet Cancer Therapeutics Market?

Growing consciousness of pet’s health and increasing incidences of cancer among animals are driving the demand for the global Pet Cancer Therapeutics market.

Who are the top players operating in the Global Pet Cancer Therapeutics Market?

C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are the key players operating in the global Pet Cancer Therapeutics market.

What are the key factors hampering growth for the Global Pet Cancer Therapeutics Market?

Adverse effects due to cancer therapeutics in pets and the ignorance of pet owners to put their pets on medications are curbing the growth of pet cancer therapeutics market. Also, limited number of veterinary oncologists, low expenditure on pet healthcare in developing and under-developed economies will impede the growth of market.